Mangoceuticals shares surge 21.43% after-hours after announcing GLP-1RA partnerships with Eli Lilly and Novo Nordisk.

Mangoceuticals surged 21.43% in after-hours trading following its announcement of a partnership with Eli Lilly and Novo Nordisk to offer GLP-1 weight-loss drugs through its telemedicine platform. The company claimed direct access to Lilly’s Zepbound and Novo’s Wegovy for program members, sparking immediate investor optimism. However, both pharmaceutical giants swiftly denied any affiliation, with Lilly stating it had previously sued Mangoceuticals and secured a permanent injunction. While the partnership was later clarified as unauthorized, the initial after-hours rally reflected market enthusiasm for the unverified claim. The subsequent intraday decline, not captured in the after-hours movement, stemmed from the denials and legal context.